论文部分内容阅读
目的:探讨分析钙剂联合骨化三醇治疗绝经后妇女骨质疏松的临床治疗效果。方法:选取2014年8月-2016年10月在我院治疗绝经后妇女骨质疏松的患者50例。将其随机分为对照组和实验组,每组各25例。对照组患者使用钙尔奇D进行治疗,实验组患者将钙尔奇D和骨化三醇联合治疗,所有患者都持续治疗6-12个月后,对其治疗前后的骨密度(BMD)、骨钙素(BGP)、血清IL-6、TNF-a的变化情况进行检测比较。结果:治疗前后对照组患者的腰椎侧位(L_(2-4))BMD、血清BGP、IL-6、TNF-a之间的差异没有统计学意义(P>0.05)。经过治疗后,实验组患者的腰椎侧位(L_(2-4))BMD、血清BGP显著的高于治疗前(P<0.05)。实验组患者治疗后的血清IL-6、TNF-a浓度等都低于治疗前(P<0.05)。结论:对绝经后妇女骨质疏松的治疗采用钙剂联合骨化三醇进行治疗,效果显著,大大的提高了患者的BMD、BGD水平,使得血清IL-6、TNF-a浓度显著的降低,临床上值得推广应用。
Objective: To investigate the clinical effects of calcium combined with calcitriol in the treatment of postmenopausal women with osteoporosis. Methods: Fifty patients with osteoporosis were treated in our hospital from August 2014 to October 2016. They were randomly divided into control group and experimental group, 25 cases in each group. Patients in the control group were treated with Calcium D, patients in the experimental group were treated with combination of Calcium D and calcitriol, and all patients were treated for 6 to 12 months. The BMD, Osteocalcin (BGP), serum IL-6, TNF-a changes were detected and compared. Results: There was no significant difference in BMD, BGP, IL-6 and TNF-a between the lumbar vertebrae and the control group before and after treatment (P> 0.05). After treatment, the experimental group of patients with lumbar lateral (L_ (2-4)) BMD, serum BGP was significantly higher than before treatment (P <0.05). The levels of IL-6 and TNF-a in the experimental group were lower than those before treatment (P <0.05). Conclusion: The treatment of osteoporosis in postmenopausal women with calcium combined with calcitriol, the effect is significant, greatly improving the patient’s BMD, BGD levels, making the serum IL-6, TNF-a significantly reduced, Clinically worth promoting application.